Business Description

Perrigo Co. Plc, a healthcare company, is involved in the distribution and production of specialty pharmaceutical products and over-the-counter consumer goods. Luther Perrigo founded the company in 1887. It is headquartered in Dublin in Ireland. It operates in three segments: Prescription Pharmaceuticals, Consumer Healthcare International, and Consumer Healthcare Americas is its primary business.

Consumer Healthcare Americas includes the U.S. and Canada consumer healthcare businesses. Consumer Healthcare International includes branded consumer healthcare businesses primarily in Europe, as well as consumer-focused businesses in Israel, Australia, and the U.K. Prescription Pharmaceuticals is the U.S. prescription drug business.

Key Financials

Revenue (US$ Mn)

• Perrigo Co. Plc’s annual revenue for 2021 was US$ 4,139 Mn, a 1.24% increase from 2020
• The annual revenue generated by Perrigo Co. Plc in 2020 was US$ 4,088 Mn
• At a -18.2% decrease from , Perrigo Co. Plc’s annual revenue of US$ 3,870 Mn was indexed in 2019
• Perrigo Co. Plc generated total revenue of US$ 4,731 Mn in 2018

 

Operating Income (US$ Mn)

• Perrigo Co. Plc’s operating income for 2021 was US$ 69 Mn, a -57.63% decrease from 2020
• The operating income generated by Perrigo Co. Plc in 2020 was US$ 163 Mn
• At an 11.53% increase, Perrigo Co. Plc’s operating income of US$ 146 Mn was indexed in 2019
• Perrigo Co. Plc generated an operating income of US$ 131 Mn in 2018

 

Net Income (US$ Mn)

• Perrigo Co. Plc’s net income for 2021 was US$ 410 Mn, a 54.75% increase from 2020
• The net income generated by Perrigo Co. Plc in 2020 was US$ 265 Mn
• At a -63.68% decrease from, Perrigo Co. Plc’s net income of US$ 175 Mn was indexed in 2019
• Perrigo Co. Plc generated a net income of US$ 481 Mn in 2018

 

Operating Margin %

• 10% was the operating margin generated by Perrigo Co. Plc in 2021
• Perrigo Co. Plc’s operating margin for 2020 was 6%, a 42.22% increase from 2019
• From 2018’s operating margins, Perrigo Co. Plc registered a -55.88% decrease in 2019, amounting to 5%
• An operating margin of 10% was generated in 2018 by Perrigo Co. Plc

 

Gross Margin %

• Perrigo Co. Plc’s gross margin for 2021 was 34%, a -6.3% decrease from 2020
• The gross margin generated by Perrigo Co. Plc in 2020 was 37%
• At a -4.39% decrease from, Perrigo Co. Plc’s gross margin of 37% was indexed in 2019
• Perrigo Co. Plc generated a gross margin of 39% in 2018

 

SWOT Analysis

Strengths

The strong performance of Consumer Healthcare Americas (CHCA)

Perrigo’s FY2017 revenue stream was dominated by the CHCA segment. It sells OTC brand products including products for the cold, allergies, and sinus. The product portfolio of this segment includes analgesics, cough/cold/allergy/sinus, gastrointestinal, infant Nutritionals, smoking cessation, and animal health.

Consumer healthcare products are sold to customers through retail stores and under the Good Sense, Sergeants, and Zephrex D brand names. This segment was responsible for 49.1% of the company’s total revenue during FY2017.